Single antiplatelet treatment with Ticagrelor or Aspirin after Transcatheter Aortic Valve Implantation: multicenter randomized clinical trial

Severe Symptomatic Aortic Stenosis

All-cause mortality at 12 months after TAVI, Transient ischemic attack (TIA) or stroke at 12 months after TAVI, Myocardial infarction at 12 months after TAVI, Bleeding at 12 months after TAVI according BARC, Net Adverse Clinical Event(s)

All major bleeding (type 2, 3 and 5) at 12 months after TAVI according BARC, Incidence of subclinical valve thrombosis (SVT) detected by hypoattenuated leaflet thickening (HALT) and reduced leaflet motion (RLM) at 3 and 12 months after TAVI assessed by 4-dimensional computed tomography (4DCT) imaging (performed only in pre-specified centers), Gender, Age, Valve type, Comorbilities, All-caused mortality at 12 months after TAVI, Stroke/TIA at 12 months after TAVI, Myocardial infarction at 12 months after TAVI, Progressive angina leading to emergency evaluation, rehospitalization or new coronary angiography at 12 months after TAVI, Thrombotic and bleeding risk score

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Italy, Portugal, Spain